The Assessment and Management of Cardiovascular Risk 🔍
National Heart Foundation of New Zealand; Stroke Foundation of New Zealand; New Zealand. Ministry of Health; New Zealand Guidelines Group
New Zealand Guidelines Group Incorporated, Best practice evidence-based guideline, Best practice evidence-based guideline, Wellington, N.Z, New Zealand, 2003
英语 [en] · PDF · 2.2MB · 2003 · 📘 非小说类图书 · 🚀/lgli/lgrs/nexusstc/zlib · Save
描述
Purpose......Page 9
About the Guideline......Page 11
Summary......Page 23
CHAPTERS......Page 5
1 Background......Page 31
2 Cardiovascular Health of Maori......Page 33
3 Cardiovascular Risk Assessment......Page 39
Targeting cardiovascular risk assessment......Page 40
Absolute cardiovascular risk assessment......Page 41
Cardiovascular risk factors......Page 42
Measurement of risk factors......Page 46
How to determine cardiovascular risk......Page 47
4 Treatment Decisions......Page 51
5 Intervention: Cardioprotective Dietary Patterns......Page 55
Cardioprotective Dietary Patterns......Page 57
Dietary interventions that reduce morbidity and mortality......Page 66
Population health approach......Page 69
Assessment of physical activity......Page 71
Risks of physical activity......Page 74
Physical activity interventions......Page 75
7 Intervention: Weight Management......Page 77
8: Classification of overweight in adults according to BMI......Page 78
Weight management interventions......Page 79
8 Intervention: Smoking Cessation......Page 87
9 Intervention: Lipid Modification......Page 89
Lipids and cardiovascular risk......Page 90
Dietary interventions that modify risk......Page 91
Drug interventions that modify lipids......Page 95
14: Doses of various statins required to reach a target......Page 99
Monitoring and duration of treatment......Page 101
10 Intervention: Blood Pressure Lowering......Page 103
Blood pressure and cardiovascular risk......Page 104
Dietary interventions that reduce blood pressure......Page 107
Drug interventions that lower blood pressure......Page 109
20: Target blood pressure levels......Page 113
Monitoring and duration of treatment......Page 114
11 Intervention: Antiplatelet Therapy......Page 115
12 Intervention: Complementary and Alternative Therapies......Page 117
13 Management of People with Diabetes, Hyperglycaemic States or The Metabolic Syndrome......Page 119
Diagnostic criteria for type 2 diabetes, IGT and IFG......Page 120
23: A definition of the metabolic syndrome......Page 122
Diabetes and cardiovascular risk......Page 123
Dietary interventions......Page 126
Drug interventions......Page 137
The overall goal of interventions......Page 140
24: Optimal risk factor levels in people with diabetes......Page 141
Aspirin......Page 143
Clopidogrel......Page 144
Dipyridamole......Page 146
Warfarin......Page 147
Beta-blockers......Page 148
ACE-inhibitors......Page 150
Lipid-modifying agents......Page 152
Antiarrhymthmic agents......Page 153
Calcium channel blockers......Page 154
When to start therapy after myocardial infarction or stroke......Page 155
15 Cardiovascular Health of Pacific People......Page 157
16 Implementation......Page 161
APPENDICES......Page 169
Abbreviations......Page 179
Glossary......Page 183
References......Page 189
FIGURES......Page 7
1: Recommended age levels for initiating cardiovascular risk assessment......Page 25
2: Intervention according to cardiovascular risk assessment......Page 29
2: Intervention according to cardiovascular risk assessment......Page 54
3: Cardioprotective dietary patterns......Page 58
4: Including carbohydrate in the cardioprotective dietary pattern......Page 62
5: Changing the ratio of unsaturated:saturated fatty acids......Page 65
6: Safe drinking guidelines......Page 67
7: Metabolic equivalents (METs) for selected activities......Page 73
10: A dietary strategy for weight loss and cardioprotection......Page 81
11: Checklist for evaluating a cardioprotective weight loss programme......Page 85
12: Risks for side effects from ingestion of EPA and DHA supplements......Page 94
13: The effect of various drug classes and plant sterols on lipid profi les......Page 98
15: Optimal lipid levels......Page 100
17: Acceptable blood pressure cuff dimensions for arms of different sizes......Page 105
18: Recommended investigations prior to treatment of raised blood pressure......Page 106
19: Indications and contraindications for the use of various drug classes to lower blood pressure......Page 112
22: Action following the fasting venous plasma glucose......Page 121
1: Steps in the assessment of cardiovascular risk......Page 24
2: Assessing 5-year cardiovascular risk and treatment benefit......Page 26
3: Treatment decisions based on 5-year cardiovascular risk......Page 28
4: Jones model on the impact of racism on health......Page 36
5: Stepwise approach to glycaemic control in type 2 diabetes......Page 139
6: A framework for performance indicators......Page 167
About the Guideline......Page 11
Summary......Page 23
CHAPTERS......Page 5
1 Background......Page 31
2 Cardiovascular Health of Maori......Page 33
3 Cardiovascular Risk Assessment......Page 39
Targeting cardiovascular risk assessment......Page 40
Absolute cardiovascular risk assessment......Page 41
Cardiovascular risk factors......Page 42
Measurement of risk factors......Page 46
How to determine cardiovascular risk......Page 47
4 Treatment Decisions......Page 51
5 Intervention: Cardioprotective Dietary Patterns......Page 55
Cardioprotective Dietary Patterns......Page 57
Dietary interventions that reduce morbidity and mortality......Page 66
Population health approach......Page 69
Assessment of physical activity......Page 71
Risks of physical activity......Page 74
Physical activity interventions......Page 75
7 Intervention: Weight Management......Page 77
8: Classification of overweight in adults according to BMI......Page 78
Weight management interventions......Page 79
8 Intervention: Smoking Cessation......Page 87
9 Intervention: Lipid Modification......Page 89
Lipids and cardiovascular risk......Page 90
Dietary interventions that modify risk......Page 91
Drug interventions that modify lipids......Page 95
14: Doses of various statins required to reach a target......Page 99
Monitoring and duration of treatment......Page 101
10 Intervention: Blood Pressure Lowering......Page 103
Blood pressure and cardiovascular risk......Page 104
Dietary interventions that reduce blood pressure......Page 107
Drug interventions that lower blood pressure......Page 109
20: Target blood pressure levels......Page 113
Monitoring and duration of treatment......Page 114
11 Intervention: Antiplatelet Therapy......Page 115
12 Intervention: Complementary and Alternative Therapies......Page 117
13 Management of People with Diabetes, Hyperglycaemic States or The Metabolic Syndrome......Page 119
Diagnostic criteria for type 2 diabetes, IGT and IFG......Page 120
23: A definition of the metabolic syndrome......Page 122
Diabetes and cardiovascular risk......Page 123
Dietary interventions......Page 126
Drug interventions......Page 137
The overall goal of interventions......Page 140
24: Optimal risk factor levels in people with diabetes......Page 141
Aspirin......Page 143
Clopidogrel......Page 144
Dipyridamole......Page 146
Warfarin......Page 147
Beta-blockers......Page 148
ACE-inhibitors......Page 150
Lipid-modifying agents......Page 152
Antiarrhymthmic agents......Page 153
Calcium channel blockers......Page 154
When to start therapy after myocardial infarction or stroke......Page 155
15 Cardiovascular Health of Pacific People......Page 157
16 Implementation......Page 161
APPENDICES......Page 169
Abbreviations......Page 179
Glossary......Page 183
References......Page 189
FIGURES......Page 7
1: Recommended age levels for initiating cardiovascular risk assessment......Page 25
2: Intervention according to cardiovascular risk assessment......Page 29
2: Intervention according to cardiovascular risk assessment......Page 54
3: Cardioprotective dietary patterns......Page 58
4: Including carbohydrate in the cardioprotective dietary pattern......Page 62
5: Changing the ratio of unsaturated:saturated fatty acids......Page 65
6: Safe drinking guidelines......Page 67
7: Metabolic equivalents (METs) for selected activities......Page 73
10: A dietary strategy for weight loss and cardioprotection......Page 81
11: Checklist for evaluating a cardioprotective weight loss programme......Page 85
12: Risks for side effects from ingestion of EPA and DHA supplements......Page 94
13: The effect of various drug classes and plant sterols on lipid profi les......Page 98
15: Optimal lipid levels......Page 100
17: Acceptable blood pressure cuff dimensions for arms of different sizes......Page 105
18: Recommended investigations prior to treatment of raised blood pressure......Page 106
19: Indications and contraindications for the use of various drug classes to lower blood pressure......Page 112
22: Action following the fasting venous plasma glucose......Page 121
1: Steps in the assessment of cardiovascular risk......Page 24
2: Assessing 5-year cardiovascular risk and treatment benefit......Page 26
3: Treatment decisions based on 5-year cardiovascular risk......Page 28
4: Jones model on the impact of racism on health......Page 36
5: Stepwise approach to glycaemic control in type 2 diabetes......Page 139
6: A framework for performance indicators......Page 167
备用文件名
lgli/_366702.91229447c749f0e84bb142558036f18c.pdf
备用文件名
lgrsnf/_366702.91229447c749f0e84bb142558036f18c.pdf
备用文件名
zlib/no-category/New Zealand Guidelines Group/The Assessment and Management of Cardiovascular Risk_1081698.pdf
备用出版商
Author-publishers (miscellaneous)
备用版本
New Zealand, New Zealand
元数据中的注释
до 2011-08
元数据中的注释
lg642638
元数据中的注释
{"isbns":["0476000912","9780476000919"],"last_page":220}
元数据中的注释
"December 2003."
Includes bibliographical references (p. 159-190).
Also available online.
Includes bibliographical references (p. 159-190).
Also available online.
开源日期
2011-08-31
🚀 快速下载
成为会员以支持书籍、论文等的长期保存。为了感谢您对我们的支持,您将获得高速下载权益。❤️
如果您在本月捐款,您将获得双倍的快速下载次数。
🐢 低速下载
由可信的合作方提供。 更多信息请参见常见问题解答。 (可能需要验证浏览器——无限次下载!)
- 低速服务器(合作方提供) #1 (稍快但需要排队)
- 低速服务器(合作方提供) #2 (稍快但需要排队)
- 低速服务器(合作方提供) #3 (稍快但需要排队)
- 低速服务器(合作方提供) #4 (稍快但需要排队)
- 低速服务器(合作方提供) #5 (无需排队,但可能非常慢)
- 低速服务器(合作方提供) #6 (无需排队,但可能非常慢)
- 低速服务器(合作方提供) #7 (无需排队,但可能非常慢)
- 低速服务器(合作方提供) #8 (无需排队,但可能非常慢)
- 低速服务器(合作方提供) #9 (无需排队,但可能非常慢)
- 下载后: 在我们的查看器中打开
所有选项下载的文件都相同,应该可以安全使用。即使这样,从互联网下载文件时始终要小心。例如,确保您的设备更新及时。
外部下载
-
对于大文件,我们建议使用下载管理器以防止中断。
推荐的下载管理器:JDownloader -
您将需要一个电子书或 PDF 阅读器来打开文件,具体取决于文件格式。
推荐的电子书阅读器:Anna的档案在线查看器、ReadEra和Calibre -
使用在线工具进行格式转换。
推荐的转换工具:CloudConvert和PrintFriendly -
您可以将 PDF 和 EPUB 文件发送到您的 Kindle 或 Kobo 电子阅读器。
推荐的工具:亚马逊的“发送到 Kindle”和djazz 的“发送到 Kobo/Kindle” -
支持作者和图书馆
✍️ 如果您喜欢这个并且能够负担得起,请考虑购买原版,或直接支持作者。
📚 如果您当地的图书馆有这本书,请考虑在那里免费借阅。
下面的文字仅以英文继续。
总下载量:
“文件的MD5”是根据文件内容计算出的哈希值,并且基于该内容具有相当的唯一性。我们这里索引的所有影子图书馆都主要使用MD5来标识文件。
一个文件可能会出现在多个影子图书馆中。有关我们编译的各种数据集的信息,请参见数据集页面。
有关此文件的详细信息,请查看其JSON 文件。 Live/debug JSON version. Live/debug page.